ERBB2 and breast cancer: Pan-class I PI3K inhibitor Buparlisib failed to show any activity when given in combination with paclitaxel in HER2 negative metastatic BC patients and specifically in the TNBC subpopulation the combination was inferior compared to paclitaxel alone [101].